secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2026-06-11T20:44:20+00:00
Accession:  0001140361-26-024949
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 1.02, 2.01, 3.01, 5.01, 2.03, 3.03, 5.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chiesi completes $27/share acquisition of KalVista; shares cease trading on Nasdaq
--------------------------------------------------------------------------------

- Tender offer accepted 43,152,532 shares (~77.8% of outstanding) at $27.00 cash per share.
- Back-end merger closed June 11, 2026; KalVista now wholly owned by Chiesi Group.
- KalVista stock halted June 10 and delisted from Nasdaq Global Market effective June 11.
- Chiesi takes ownership of EKTERLY (sebetralstat), oral on-demand HAE treatment approved in US, EU, Japan.
- Transaction bonuses aggregate $10.5M for CEO, CMO, CFO; gross-up agreement with CFO for Section 4999 excise tax.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/0001140361-26-024949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/ny20075902x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-024949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer